DK0413188T3 - Fremgangsmåde til fremstilling af umodificerede, intravenøst administrerbare IgM- og/eller IgA-holdige immunglobulinpræparater - Google Patents

Fremgangsmåde til fremstilling af umodificerede, intravenøst administrerbare IgM- og/eller IgA-holdige immunglobulinpræparater

Info

Publication number
DK0413188T3
DK0413188T3 DK90114576.3T DK90114576T DK0413188T3 DK 0413188 T3 DK0413188 T3 DK 0413188T3 DK 90114576 T DK90114576 T DK 90114576T DK 0413188 T3 DK0413188 T3 DK 0413188T3
Authority
DK
Denmark
Prior art keywords
iga
igm
preparation
unmodified
immunoglobulin preparations
Prior art date
Application number
DK90114576.3T
Other languages
Danish (da)
English (en)
Inventor
Detlef Dr Dipl-Chem Piechaczek
Wolfgang Dr Dipl-Chem Moeller
Original Assignee
Biotest Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6387263&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0413188(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotest Pharma Gmbh filed Critical Biotest Pharma Gmbh
Application granted granted Critical
Publication of DK0413188T3 publication Critical patent/DK0413188T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DK90114576.3T 1989-08-17 1990-07-30 Fremgangsmåde til fremstilling af umodificerede, intravenøst administrerbare IgM- og/eller IgA-holdige immunglobulinpræparater DK0413188T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3927111A DE3927111C3 (de) 1989-08-17 1989-08-17 Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate

Publications (1)

Publication Number Publication Date
DK0413188T3 true DK0413188T3 (da) 1995-03-27

Family

ID=6387263

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90114576.3T DK0413188T3 (da) 1989-08-17 1990-07-30 Fremgangsmåde til fremstilling af umodificerede, intravenøst administrerbare IgM- og/eller IgA-holdige immunglobulinpræparater

Country Status (8)

Country Link
US (1) US5410025A (en:Method)
EP (1) EP0413188B1 (en:Method)
JP (1) JP3148222B2 (en:Method)
AT (1) ATE117900T1 (en:Method)
DE (2) DE3927111C3 (en:Method)
DK (1) DK0413188T3 (en:Method)
ES (1) ES2067600T3 (en:Method)
GR (1) GR3015229T3 (en:Method)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256771A (en) * 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
ATE182793T1 (de) * 1994-02-18 1999-08-15 Immuno Ag Zusammensetzung und verfahren zur verhinderung und behandlung von entzündung mit immunoglobin a
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0835880A1 (de) * 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6441144B1 (en) * 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
CN1358100A (zh) * 1999-06-15 2002-07-10 阿尔法治疗公司 静脉注射用免疫球蛋白及其产物的制造方法
SE0001128D0 (sv) * 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US20020098182A1 (en) * 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
WO2002026258A2 (en) * 2000-09-28 2002-04-04 Research Corporation Technologies, Inc. Treatment of immune-mediated diseases by oral administration of plasma fractions
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US20040180045A1 (en) * 2001-09-28 2004-09-16 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
DE102007001521A1 (de) 2007-01-10 2008-07-17 Matthias, Torsten, Dr. Verwendung von Cohn-Oncley-Fraktionen II und II/III zur Behandlung des systemischen Lupus erythematodes
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
US10221233B2 (en) * 2012-03-09 2019-03-05 Csl Behring Ag Compositions comprising secretory-like immunoglobulins
US10570194B2 (en) 2015-08-06 2020-02-25 Grifols Worldwide Operations Limited Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
US9913903B2 (en) 2015-08-06 2018-03-13 Grifols Worldwide Operations Limited Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
EP3275897A1 (en) 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
BR112022020211A2 (pt) * 2020-04-10 2022-11-22 Vanudis GmbH Anticorpos naturais em profilaxia e terapia

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3808189A (en) * 1973-03-15 1974-04-30 American Cyanamid Co Isolation of gamma globulin preparations enriched in iga and igm using polyethylene glycol
DE2404265C3 (de) * 1974-01-30 1980-05-29 Behringwerke Ag, 3550 Marburg Verfahren zum Abreichen von Immunglobulinen
DE2527064C3 (de) * 1975-06-18 1979-11-15 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines intravenösen Nativ-Human-Immunglobulin-Präparates mit natürlicher Halbwertszeit und gegenüber dem Ausgangsmaterial unveränderten Antikörperaktivität
DE2835843A1 (de) * 1978-08-16 1980-02-28 Blutspendedienst Dt Rote Kreuz Verfahren zur herstellung einer fuer die intravenoese anwendung geeigneten gammaglobulinloesung
DE2901822A1 (de) * 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
DE3271181D1 (en) * 1982-02-08 1986-06-19 Schweiz Serum & Impfinst Intravenously administrable human immunoglobuline and process for its preparation
US4639513A (en) * 1984-02-02 1987-01-27 Cuno Inc. Intravenously injectable immunoglobulin G (IGG) and method for producing same
DE3310150A1 (de) * 1983-03-21 1984-09-27 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
US4613501A (en) * 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
NZ216094A (en) * 1985-05-15 1989-06-28 Commw Serum Lab Commission Method for purification of an immunoglobulin
US5159064A (en) * 1986-04-08 1992-10-27 Miles Inc. Preparation of virus-free antibodies
DE3640513A1 (de) * 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt

Also Published As

Publication number Publication date
DE59008404D1 (de) 1995-03-16
US5410025A (en) 1995-04-25
EP0413188B1 (de) 1995-02-01
DE3927111A1 (de) 1991-02-21
DE3927111C3 (de) 1994-09-01
EP0413188A2 (de) 1991-02-20
JPH03204822A (ja) 1991-09-06
JP3148222B2 (ja) 2001-03-19
ATE117900T1 (de) 1995-02-15
EP0413188A3 (en) 1991-06-05
ES2067600T3 (es) 1995-04-01
DE3927111C2 (en:Method) 1991-11-28
GR3015229T3 (en) 1995-05-31

Similar Documents

Publication Publication Date Title
DK0413188T3 (da) Fremgangsmåde til fremstilling af umodificerede, intravenøst administrerbare IgM- og/eller IgA-holdige immunglobulinpræparater
TAUROG Thyroid peroxidase and thyroxine biosynthesis
NO170126C (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater i form av suspensjoner som inneholder sucralfat
KR860002277A (ko) 면역 글로부린의 비루스-불활성화 방법
ES515177A0 (es) Procedimiento para el tratamiento de inmunoglobulina de suero.
EP0530447A3 (en) Process for purifying igg monoclonal antibodies and their use
DE2962569D1 (en) Immune serum globulin preparations and method to produce them
NO864971L (no) Fremgangsmaate for fremstilling av monoklonale antistoffer som er kryssbeskyttende overfor p. aeruginosaserotyper.
ES512087A0 (es) "procedimiento de preparacion de organopolisiloxanos de peso molecular elevado".
DK163181C (da) Analogifremgangsmaade til fremstilling af n,n'-di(arylalkylen)alkylendiaminer eller farmaceutisk acceptable salte deraf
PT85490A (en) Process for the preparation of specific monoclonal antibodies of apolipoprotein-b and essay processes for the determination o the above mentioned apolipoprotein
ES2165884T3 (es) Preparacion farmaceutica estable que no contiene actividad viral consistente en al menos un 70%, preferiblemente un 90% de inmunoglobulina a humana monomera, y procedimiento de preparacion.
AU6284386A (en) Inhibition of in vitro infectivity and cytopathic effect of htlv-111/lav by 2' 3' -dideoxycytidine
FI880954A7 (fi) Seos ja menetelmä immunologista kastrointia varten.
JPS5615215A (en) Preparation of human immunoglobulin for intravenous injection with immobilized pepsin gel
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
AU6089086A (en) Treatment of chronic inflammatory disease
FI871368A7 (fi) Menetelmä 2,3,4,5-tetrafluori -bentsoyyliasetaattien valmistamiseksi.
AU545065B2 (en) Pharmaceutical formulations containing prostaglandin
DENG PURIFICATION OF HUMAN INTERFERON-? BY ANTIBODY AFFINITY CHROMATOGRAPY
FI810591A7 (fi) Menetelmä N,N-dimetyyli /atsa-1 bisyklo(2,2,2)oktyyli-3/-10 10H-feno- tiatsiinisulfoniamidi-2'n valmisvalmistamiseksi.
ATE59860T1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
DK551183A (da) Substituerede 9h-8-oxo-pyrimido(2,1-f)purin-2,4-dioner, fremgangsmaade til deres fremstilling og farmaceutiske kompositioner indeholdende forbindelserne
ATE18994T1 (de) Neue pharmazeutische zusammensetzung.